E
E. Chester Ridgway
Researcher at University of Colorado Denver
Publications - 108
Citations - 6133
E. Chester Ridgway is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Thyroid & Thyrotropic cell. The author has an hindex of 42, co-authored 108 publications receiving 5922 citations. Previous affiliations of E. Chester Ridgway include Anschutz Medical Campus & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
Bryan R. Haugen,Furio Pacini,Christoph Reiners,Martin Schlumberger,Paul W. Ladenson,Steven I. Sherman,David S. Cooper,Kathryn E. Graham,Lewis E. Braverman,Monica C. Skarulis,Terry F. Davies,Leslie J. DeGroot,Ernest L. Mazzaferri,Gilbert H. Daniels,Douglas S. Ross,Markus Luster,Mary H. Samuels,David V. Becker,Harry R. Maxon,Ralph R. Cavalieri,Carole A. Spencer,Kevin McEllin,Bruce D. Weintraub,E. Chester Ridgway +23 more
TL;DR: Comparing the effect of administered recombinant TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning (WBS) and serum thyroglobulin (Tg) levels found recombinant human TSH administration is a safe and effective means of stimulatingRadioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence.
Journal ArticleDOI
Subclinical Hypothyroidism Is Mild Thyroid Failure and Should be Treated
Journal ArticleDOI
Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia
Paul W. Ladenson,Jens D. Kristensen,E. Chester Ridgway,Anders G. Olsson,Bo Carlsson,Irwin Klein,John D. Baxter,Bo Angelin +7 more
TL;DR: In this 12-week trial, the thyroid hormone analogue eprotirome was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment with statins.
Journal ArticleDOI
Subclinical Hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-Thyroxine
TL;DR: It is concluded that prolonged suppressive L-thyroxine treatment may result in mild subclinical hyperthyroidism with adverse effects on bone and patients requiring suppression of the pituitary-thyroid axis should be given the smallest dose of L- thyroxine necessary to achieve a satisfactory clinical response.
Journal ArticleDOI
Osteoporosis in Men with Hyperprolactinemic Hypogonadism
TL;DR: The data show that chronic hyperprolactinemia and testosterone deficiency in men have deleterious and previously unrecognized extragonadal effects that may be alleviated after normalization of hormone concentrations.